ASCO 2019 Kidney Cancer

Viewing 1-20 of 29 articles

ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology

ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma

ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features

ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma

ASCO 2019: KEYNOTE-427 Cohort B: First-Line Pembrolizumab Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma

ASCO 2019: First-Line Pembrolizumab Monotherapy in Advanced Clear Cell Renal Cell Carcinoma: Updated Results for KEYNOTE-427 Cohort A

ASCO 2019: Balancing Disease Control and Quality of Life in Metastatic Renal Cell Carcinoma

ASCO 2019: Sarcomatoid RCC: Defining a New Treatment Paradigm?

ASCO 2019: First-Line Immuno-oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International mRCC Database Consortium

ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis - Medical Oncologist Perspective

ASCO 2019: Safety and Efficacy of Nivolumab plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma with Brain Metastases: Interim Analysis of CheckMate 920

ASCO 2019: Consistent Efficacy of Nivolumab plus Ipilimumab Across a Number of International Metastatic Database Consortium Risk Factors in CheckMate 214

ASCO 2019: Integrating Local and Systemic Modalities in Bladder and Renal Cancers

ASCO 2019: Retrospective Analysis of the Safety and Efficacy of Immune Checkpoint Inhibitors among Patients with Pre-Existing Autoimmune Disorders and Renal Cell Carcinoma or Urothelial Carcinoma

ASCO 2019: Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

ASCO 2019: Evolving Front-Line Therapy in Metastatic Renal Cell Carcinoma

ASCO 2019: Update on the CARMENA Trial with Focus on Intermediate IMDC-risk Population: Cytoreductive Nephrectomy in Metastatic Renal Cancer

ASCO 2019: Pembrolizumab Plus Axitinib versus Sunitinib as First-Line Therapy for mRCC: Outcomes in the Combined IMDC Intermediate/Poor Risk and Sarcomatoid Subgroups of the Phase 3 KEYNOTE-426 Study

ASCO 2019: Deferred Cytoreductive Nephrectomy Among Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma Treated Initially with Sunitinib

ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with mRCC who have no Evidence of Disease Following Metastasectomy: A Trial of the ECOG-ACRIN Cancer Research Group

1
2